About ZYBIRAA 250MG
ZYBIRAA 250MG is a spectacular oncology masterpiece, highly recommended by leading professionals. Formulated with Abiraterone Acetate (250mg per tablet) and expertly manufactured in India, this dazzling pharmaceutical product is specifically designed for the treatment of metastatic castration-resistant prostate cancer. Each bottle contains 120 white to off-white, oval-shaped, film-coated tablets-available exclusively by prescription. ZYBIRAA is CDSCO-approved, ensuring safety and efficacy. With a shelf life of 24 months and room-temperature storage, this promotion is a must-select for distributors, suppliers, and traders seeking a remarkable addition to their portfolio.
ZYBIRAA 250MG: Suitable Use and Versatile Applications
Select ZYBIRAA 250MG for the expert management of metastatic castration-resistant prostate cancer, making it suitable for adults under oncologist supervision. Its oral administration ensures patient convenience and adherence to prescribed protocols. While primarily intended for pharmaceutical oncology applications, the spectacular film-coated tablets offer broad utility in clinical settings throughout India. Its application surface covers both hospital and specialty pharmacy environments, making it a dazzling choice for trusted care teams.
ZYBIRAA 250MG: Reliable Supply, Fast Shipping, and Flexible Payment
ZYBIRAA 250MG demonstrates strong supply ability, ready for seamless export to international and domestic markets. Benefit from our express shipping options and secure global transportation network, ensuring that this highly recommended product arrives swiftly and safely. Enjoy flexible payment terms and transparent sample policies to streamline procurement for distributors, suppliers, and traders. Reliability and efficiency define our approach, making ZYBIRAA 250MG a preferred selection in worldwide pharmaceutical distribution.
FAQ's of ZYBIRAA 250MG:
Q: How should ZYBIRAA 250MG tablets be stored for maximum potency?
A: ZYBIRAA 250MG tablets should be stored at room temperature, away from moisture and direct sunlight, to preserve their efficacy throughout the 24-month shelf life.
Q: What is the primary usage of ZYBIRAA 250MG in clinical practice?
A: ZYBIRAA 250MG is indicated for the treatment of metastatic castration-resistant prostate cancer and should only be administered under prescription by a qualified oncologist.
Q: When can a patient expect to begin treatment with ZYBIRAA 250MG?
A: Patients may start ZYBIRAA 250MG once it is prescribed by their healthcare provider, following a thorough evaluation of their medical condition and treatment suitability.
Q: Where is ZYBIRAA 250MG approved and manufactured?
A: ZYBIRAA 250MG is approved by India's CDSCO and is distributed, supplied, and traded across the Indian and export pharmaceutical markets.
Q: What is the benefit of selecting ZYBIRAA 250MG for distributors or traders?
A: The primary benefit is access to a highly recommended, CDSCO-approved oncology product with robust supply capacity, express shipping, and flexible payment terms for seamless procurement.